Neurotrophic keratopathy – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:14:07 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Neurotrophic keratopathy – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Effectiveness of Timbetasin Acetate Eye Drops for Patients with Neurotrophic Keratopathy https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-timbetasin-acetate-eye-drops-for-patients-with-neurotrophic-keratopathy/ Wed, 29 Apr 2026 15:02:41 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-timbetasin-acetate-eye-drops-for-patients-with-neurotrophic-keratopathy/ This clinical trial is focused on studying a condition called Neurotrophic Keratopathy, which affects the eyes. It is a disease where the cornea, the clear front part of the eye, loses its ability to heal properly due to nerve damage. The study will test a new treatment called RGN-259, which is an eye drop solution containing the active ingredient Timbetasin acetate. This treatment is designed to help the cornea heal by promoting cell growth and repair.

The purpose of the study is to compare the safety and effectiveness of RGN-259 with a placebo, which looks like the real treatment but does not contain the active ingredient. Participants in the study will be randomly assigned to receive either the RGN-259 eye drops or the placebo. The study will last for several weeks, during which participants will use the eye drops and attend regular check-ups to monitor their progress. The main goal is to see if the treatment helps heal the corneal defects associated with Neurotrophic Keratopathy.

Throughout the study, doctors will assess the healing of the cornea using special eye exams and will also check for any side effects. Participants will be asked to report any changes in their symptoms, such as discomfort or vision changes. The study aims to provide valuable information on whether RGN-259 can be a safe and effective treatment option for people with Neurotrophic Keratopathy.

]]> Study on the Safety and Effectiveness of RGN-259 Eye Drops for Patients with Neurotrophic Keratopathy https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-rgn-259-eye-drops-for-patients-with-neurotrophic-keratopathy/ Wed, 29 Apr 2026 14:24:12 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-rgn-259-eye-drops-for-patients-with-neurotrophic-keratopathy/ This clinical trial is focused on studying a condition called Neurotrophic Keratopathy, which affects the eyes. It is a disease where the cornea, the clear front part of the eye, loses its sensitivity and ability to heal properly. The treatment being tested in this study is an eye drop solution called Timbetasin acetate ophthalmic solution 0.1%, also known by its code name RGN-259. This solution is designed to help heal the cornea and improve eye health.

The purpose of the study is to compare the safety and effectiveness of RGN-259 with a placebo, which looks like the real treatment but does not contain the active ingredient. Participants in the study will be randomly assigned to receive either the RGN-259 eye drops or the placebo. The study is conducted in a way that neither the participants nor the researchers know who is receiving the actual treatment, which helps ensure unbiased results.

Throughout the study, participants will use the eye drops for a period of up to four weeks. They will have regular check-ups to monitor the healing of their corneal defects and to assess any changes in their eye condition. The study aims to determine if the RGN-259 eye drops can effectively heal the cornea and improve symptoms associated with Neurotrophic Keratopathy.

]]>